ArticleAnnals of nuclear medicine2026
Effect of previous
Article in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study evaluates the impact of prior PRRT with Lu-177 DOTATATE on the response to TARE in NET patients with liver metastases.
methodsTwenty-one patients who underwent TARE after PRRT between 2015 and 2022 were retrospectively analyzed. Tumor-specific cumulative Lu-177 DOTATATE counts were calculated from SPECT/CT images. Treatment planning was conducted with a standard target dose of 150 Gy to the tumoral tissue. Treatment response was assessed using changes in SUVmax, SUVmean, and somatostatin receptor-expressing tumor volume (SRE-TV) values derived from Ga-68 DOTATATE PET/CT before and 2-4 months after TARE. Lesion size was evaluated using RECIST v1.1 criteria. Dosimetry calculations were performed on Tc-99 m MAA SPECT/CT and Y-90 microsphere PET/MRI using Simplicit90Y™. Statistical analyses included Spearman correlation and Kruskal-Wallis tests.
resultsThe median age of patients was 56 years (range 36-78 years). PRRT involved a mean cumulative Lu-177 DOTATATE dose of 43.5 ± 13.4 GBq (1175 ± 362 mCi). Post-TARE reductions in SUVmax (38.49 ± 20.46 to 19.94 ± 10.43 g/mL), SUVmean (9.51 ± 5.60 to 5.39 ± 3.64 g/mL), and SRE-TV (217.43 ± 155.87 to 175.62 ± 147.77 cm
conclusionPrior PRRT does not significantly affect TARE response in NET patients with liver metastases. Radioembolization planning should prioritize factors like tumor, target, or healthy liver doses over previous PRRT.
Indexed as
Identifiers
40855138What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.